Novartis to buy cancer drugmaker Endocyte for $2.1 Billion in cash
Novartis AG will acquire U.S. based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radio pharmaceuticals business, the companies said on Thursday.The $24-per-share offer represents a premium of 54 percent to Endocyte's Wednesday closing price.
Endocyte said the deal will help develop a broader role for radioligand therapies in cancer treatment.
The deal will also enable Novartis to investigate the potential development of a drug candidate for use in earlier lines of prostate cancer therapy, it said.
Endocyte will be merged with a newly formed Novartis subsidiary, they said. The transaction is expected to be completed in the first half of 2019 and Endocyte will continue to operate as a separate and independent company until then.
Novartis said in September that it will cut 2,550 jobs in Switzerland and Britain over four years, as the it strives to boost profits and focus on new medicines.
cancer drugmakercancer treatmentEndocytenew medicinesNovartisprostate cancer therapyradio pharmaceuticals businessradioligand therapiesSwiss drugmaker
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd